Cancer Family
Malignant Mixed Neoplasm
CI-CAN-00000241Explore in graph →
96 active trials1 approved drugs4 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000241Explore in graph →
Clinical trials
348 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (43)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00989651 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 431 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02015819 | Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 16 | City of Hope Medical CenterOTHER | 1 | Oct 20, 2021 |
| clinicaltrials |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | unknown | Phase 3 | 1,157 | GOG FoundationNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | unknown | Phase 3 | 637 | GOG FoundationNETWORK | 2 | Sep 30, 2021 | clinicaltrials |
| NCT02993705 | Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)(MITO 26) | completed | Phase 2 | 45 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT03933761 | Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy(PRECISE) | withdrawn | Phase 2 | 0 | Australia New Zealand Gynaecological Oncology GroupOTHER | 0 | Aug 10, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT02394652 | The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT03902379 | Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer | withdrawn | N/A | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT04814758 | DWI in the Diagnosis of Histological Types of Nephroblastoma in Children | unknown | N/A | 230 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | terminated | Phase 1 | 35 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Mar 2, 2021 | clinicaltrials |
| NCT04758455 | The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence | unknown | N/A | 75 | Mansoura UniversityOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT01365156 | Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix | completed | Phase 3 | 28 | M.D. Anderson Cancer CenterOTHER | 2 | Feb 3, 2021 | clinicaltrials |
| NCT02283658 | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT01266460 | Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 54 | Gynecologic Oncology GroupNETWORK | 1 | Sep 11, 2020 | clinicaltrials |
| NCT01711515 | Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00478426 | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 2 | Feb 17, 2020 | clinicaltrials |
| NCT00895349 | Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial)(PET LACE) | completed | N/A | 171 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT00503893 | Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies | unknown | — | 295 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01222780 | To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer | completed | Phase 1 | 22 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01991652 | Collaborative Wilms Tumour Africa Project | unknown | — | 400 | Amsterdam UMC, location VUmcOTHER | 3 | Jan 3, 2020 | clinicaltrials |
| NCT01445379 | Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00758108 | Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions | completed | — | 197 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00924066 | Ixabepilone to Treat Cervical Cancer | terminated | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00035373 | Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols | terminated | — | 767 | National Cancer Institute (NCI)NIH | 1 | Nov 7, 2019 | clinicaltrials |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT01504126 | Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Early Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 29, 2019 | clinicaltrials |
| NCT01074411 | Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2019 | clinicaltrials |
| NCT01132820 | Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01168232 | Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01247571 | Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00126581 | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | completed | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2019 | clinicaltrials |
| NCT00025506 | Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00075400 | Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00262821 | Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer | terminated | Phase 3 | 402 | National Cancer Institute (NCI)NIH | 2 | Jul 23, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00803062 | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | completed | Phase 3 | 452 | National Cancer Institute (NCI)NIH | 2 | Jul 23, 2019 | clinicaltrials |
| NCT01011933 | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01459380 | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01281852 | Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2019 | clinicaltrials |
| NCT00011414 | Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2019 | clinicaltrials |
| NCT02851693 | Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection(OCTSKIN) | withdrawn | N/A | 0 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 0 | Apr 4, 2019 | clinicaltrials |
| NCT03892330 | Combination Therapy of Anthracyclines for Children With Nephroblastoma | not yet recruiting | Phase 4 | 120 | Shengjing HospitalOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT01267253 | Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01295502 | Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer | unknown | Phase 1 | 45 | Gynecologic Oncology GroupNETWORK | 1 | Mar 12, 2019 | clinicaltrials |
| NCT01489371 | EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 1 | 16 | Gynecologic Oncology GroupNETWORK | 1 | Mar 12, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Oct 20, 2021source: clinicaltrials